DE602005018181D1 - Materialien und methoden zur behandlung von koagulationsstörungen - Google Patents

Materialien und methoden zur behandlung von koagulationsstörungen

Info

Publication number
DE602005018181D1
DE602005018181D1 DE602005018181T DE602005018181T DE602005018181D1 DE 602005018181 D1 DE602005018181 D1 DE 602005018181D1 DE 602005018181 T DE602005018181 T DE 602005018181T DE 602005018181 T DE602005018181 T DE 602005018181T DE 602005018181 D1 DE602005018181 D1 DE 602005018181D1
Authority
DE
Germany
Prior art keywords
sub
compounds
methods
materials
salts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602005018181T
Other languages
German (de)
English (en)
Inventor
Pascal Druzgala
Cyrus Becker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Espero Biopharma Inc
Original Assignee
ARYx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/822,129 external-priority patent/US7145020B2/en
Application filed by ARYx Therapeutics Inc filed Critical ARYx Therapeutics Inc
Publication of DE602005018181D1 publication Critical patent/DE602005018181D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/42—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4
    • C07D311/56—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 without hydrogen atoms in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
DE602005018181T 2004-04-08 2005-04-08 Materialien und methoden zur behandlung von koagulationsstörungen Expired - Lifetime DE602005018181D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56112104P 2004-04-08 2004-04-08
US10/822,129 US7145020B2 (en) 2001-04-24 2004-04-08 Materials and methods for treating coagulation disorders
PCT/US2005/012091 WO2005100336A1 (en) 2004-04-08 2005-04-08 Materials and methods for treating coagulation disorders

Publications (1)

Publication Number Publication Date
DE602005018181D1 true DE602005018181D1 (de) 2010-01-21

Family

ID=34965219

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005018181T Expired - Lifetime DE602005018181D1 (de) 2004-04-08 2005-04-08 Materialien und methoden zur behandlung von koagulationsstörungen

Country Status (17)

Country Link
US (1) US7285671B2 (enExample)
EP (1) EP1735296B1 (enExample)
JP (1) JP5036532B2 (enExample)
KR (1) KR101203124B1 (enExample)
AT (1) ATE451361T1 (enExample)
AU (1) AU2005233614C1 (enExample)
BR (1) BRPI0508392A (enExample)
CA (1) CA2559568C (enExample)
CY (1) CY1109763T1 (enExample)
DE (1) DE602005018181D1 (enExample)
DK (1) DK1735296T3 (enExample)
ES (2) ES2436298T3 (enExample)
IL (1) IL178122A (enExample)
NO (1) NO338837B1 (enExample)
PT (1) PT1735296E (enExample)
RU (1) RU2495034C2 (enExample)
WO (1) WO2005100336A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6864279B2 (en) * 2001-04-24 2005-03-08 Aryx Therapeutics Materials and methods for treating coagulation disorders
EP2161261B1 (en) * 2004-04-08 2013-08-28 Armetheon, Inc. Materials and methods for treating coagulation disorders
DK1954669T3 (en) * 2005-12-01 2015-10-12 Auspex Pharmaceuticals Inc SUBSTITUTED phenethylamines a serotonergic AND / OR NOREPINEPHRINERG ACTIVITY
CN101188435B (zh) * 2007-01-08 2011-03-16 中兴通讯股份有限公司 一种比特交织装置与方法
WO2009119537A1 (ja) 2008-03-26 2009-10-01 第一三共株式会社 ヒドロキシキノキサリンカルボキサミド誘導体
US9549912B2 (en) 2009-11-23 2017-01-24 Armetheon, Inc. Methods for treating atrial fibrillation
US20110136779A1 (en) * 2009-11-23 2011-06-09 Milner Peter G Methods for stroke reduction in atrial fibrillation patients
AU2010327936B2 (en) * 2009-12-11 2015-08-20 Nono Inc. Agents and methods for treating ischemic and other diseases
WO2011099978A1 (en) * 2010-02-12 2011-08-18 N30 Pharmaceuticals, Llc Chromone inhibitors of s-nitrosoglutathione reductase
SI2533638T1 (sl) 2010-02-12 2016-05-31 Nivalis Therapeutics, Inc. Novi inhibitorji S-nitrozoglutation reduktaze
US11234978B2 (en) 2014-01-15 2022-02-01 Southern Methodist University Inhibitors of multidrug resistance transporter P-glycoprotein
US10292982B2 (en) 2014-01-15 2019-05-21 Southern Methodist University Inhibitors of multidrug resistance transporter P-glycoprotein
US11013739B2 (en) 2014-01-15 2021-05-25 Southern Methodist University Inhibitors of multidrug resistance transporter p-glycoprotein
US9561227B2 (en) 2014-01-15 2017-02-07 Southern Methodist University Inhibitors of multidrug resistance transporter P-glycoprotein
CN114524791B (zh) * 2022-01-26 2024-01-26 江苏慧聚药业股份有限公司 替卡法林的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL108459A0 (en) 1993-02-05 1994-04-12 Opjohn Company 4-Hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl [B] pyran-2-ones useful for treating infections due to hiv and other retroviruses
US5510375A (en) 1993-11-19 1996-04-23 Warner-Lambert Company Coumarin derivatives as protease inhibitors and antiviral agents
GB9324517D0 (en) * 1993-11-30 1994-01-19 Octel Chem Ltd Process for the preparation of substituted 4-hydroxycoumarins
FR2749585B1 (fr) * 1996-06-11 1998-08-14 Hoechst Marion Roussel Inc Nouveaux derives aromatiques substitues par un ribose, leur procede de preparation et leur application comme medicaments
FR2807032B1 (fr) * 2000-03-29 2003-04-18 Warner Lambert Co Modification de la chimioselectivite lors de l'oxydation de composes organiques azotes
US6864279B2 (en) * 2001-04-24 2005-03-08 Aryx Therapeutics Materials and methods for treating coagulation disorders
US7145020B2 (en) 2001-04-24 2006-12-05 Aryx Therapeutics Materials and methods for treating coagulation disorders
CA2462913A1 (en) * 2001-10-10 2003-04-17 Aryx Therapeutics Mibefradil-based compounds as calcium channel blockers useful in the treatment of hypertension and angina
US7179838B2 (en) * 2002-07-30 2007-02-20 New Century Pharmaceuticals, Inc. Coumarin analog compounds for safer anticoagulant treatment

Also Published As

Publication number Publication date
JP5036532B2 (ja) 2012-09-26
KR20060133081A (ko) 2006-12-22
ES2340690T3 (es) 2010-06-08
IL178122A0 (en) 2006-12-31
US7285671B2 (en) 2007-10-23
CY1109763T1 (el) 2014-09-10
JP2007532575A (ja) 2007-11-15
CA2559568A1 (en) 2005-10-27
NO20065079L (no) 2006-11-03
AU2005233614A1 (en) 2005-10-27
EP1735296A1 (en) 2006-12-27
EP1735296B1 (en) 2009-12-09
HK1138265A1 (en) 2010-08-20
PT1735296E (pt) 2010-02-09
US20060287388A1 (en) 2006-12-21
DK1735296T3 (da) 2010-02-01
HK1105200A1 (en) 2008-02-06
RU2495034C2 (ru) 2013-10-10
WO2005100336A1 (en) 2005-10-27
NO338837B1 (no) 2016-10-24
RU2008120295A (ru) 2009-11-27
AU2005233614B2 (en) 2011-11-24
KR101203124B1 (ko) 2012-11-20
AU2005233614C1 (en) 2012-07-19
ES2436298T3 (es) 2013-12-30
BRPI0508392A (pt) 2007-08-07
ATE451361T1 (de) 2009-12-15
IL178122A (en) 2013-01-31
CA2559568C (en) 2013-05-28

Similar Documents

Publication Publication Date Title
CY1109763T1 (el) Υλικα και μεθοδος για τη θεραπεια διαταραχων πηξης
DE502004005033D1 (de) Substituierte 2-aminotetraline zur behandlung von depressionen
EA200602191A1 (ru) 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения
NO20084652L (no) Deazapuriner anvendelige som inhibitorer av januskinaser
NO20073140L (no) Pyrrolopyraziner og pyralopyraziner som er nyttige som inhibitorer av proteinkinaser
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
EA200601239A1 (ru) Замещённые хинолиновые соединения
NO20052595L (no) Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
ATE492542T1 (de) Herstellung und anwendung von biphenyl-4-yl- carbonylaminosäurederivaten zur behandlung von obesitas
EA200800172A1 (ru) 2,4-диаминопиримидины как ингибиторы aurora
NO20082673L (no) Nye 2-amino-imidazol-4-on forbindelser og deres anvendelse i fremstilling av et medikament som skal brukes til behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerasjon og demens
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
NO20082508L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
SE0403006D0 (sv) New compounds
EA200601802A1 (ru) Производные морфолина
NO20082096L (no) Azaindol-2-karboksamidderivativer
EA201070442A1 (ru) НОВЫЕ ИНГИБИТОРЫ sEH И ИХ ПРИМЕНЕНИЕ
DE602006010834D1 (de) Neue thiophensulfoximine zur behandlung von komplementvermittelten krankheiten und leiden
EA200700848A1 (ru) Ингибиторы pi3-гамма-киназы для лечения анемии
ATE429916T1 (de) Verwendung von sulfonamid-derivaten bei der behandlung von adipositas oder zur verringerung der nahrungsaufnahme
DE602006009556D1 (de) Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
ATE496899T1 (de) Tetrahydro- und dihydrochinazolinone
EP1597234A4 (en) NEW COMPOUNDS

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R082 Change of representative

Ref document number: 1735296

Country of ref document: EP

Representative=s name: MUELLER FOTTNER STEINECKE RECHTSANWAELTE PATEN, DE

R081 Change of applicant/patentee

Ref document number: 1735296

Country of ref document: EP

Owner name: ARMETHEON, INC. (N.D. GES. DES STAATES DELAWAR, US

Free format text: FORMER OWNER: ARYX THERAPEUTICS, FREMONT, US

Effective date: 20121019

R082 Change of representative

Ref document number: 1735296

Country of ref document: EP

Representative=s name: MUELLER FOTTNER STEINECKE RECHTSANWAELTE PATEN, DE

Effective date: 20121019